Physician profile
Michael N Lam
NPI 1528184587
$17,694.48
in general payments reported to CMS, 2019-2025
28 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,273 · 2020: $992 · 2021: $1,771 · 2022: $3,091 · 2023: $2,878 · 2024: $2,373 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,568.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,553.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $2,594.36 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Amgen INC. | $2,174.59 | 2019-2025 | Repatha, Evenity, Repatha |
| Glaxosmithkline, LLC. | $1,233.85 | 2022-2024 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $1,150.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $932.46 | 2021-2025 | |
| Abbvie INC. | $792.25 | 2019-2023 | |
| Novo Nordisk INC | $621.14 | 2021-2025 | Ozempic |
| Allergan, INC. | $600.35 | 2019-2020 | |
| Lilly USA, LLC | $543.75 | 2019-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $513.60 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $329.68 | 2019-2024 | Verquvo |
| Abbott Laboratories | $311.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $258.22 | 2019 | |
| Esperion Therapeutics, INC. | $249.98 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $249.64 | 2019 | |
| Horizon Therapeutics Plc | $248.78 | 2022-2023 | Krystexxa |
| Vivus LLC | $244.99 | 2022-2024 | Pancreaze |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Mylan Specialty L.P. | $125.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $124.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $124.95 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $114.58 | 2023 | Inpefa |
| Urovant Sciences INC | $114.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Dexcom, INC. | $99.20 | 2023 | Dexcom G7 Gss (161) |
| Galderma Laboratories, L.P. | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.